Job title：
Professor
Research theme for competitive and other funds (2)：
2023 - 2024 開発費大江班
AMED塚崎班
Papers (46)：
Watanabe T, Tobinai K, Wakabayashi M, Maruyama D, Yamamoto K, Kubota N, Shimada K, Asagoe K, Yamaguchi M, Ando K, et al. R-CHOP treatment for patients with advanced follicular lymphoma: Over 15-year follow-up of JCOG0203, 2024 Mar;204(3):849-860. Br J Haematol. 2024. 204. 3. 849-860
Shimada K, Ohmachi K, Machida R, Ota S, Itamura H, Tsujimura H, Takayama N, Shimada T, Kurosawa M, Tabayashi T, et al. Secondary central nervous system involvement in patients with diffuse large B-cell lymphoma treated with rituximab combined CHOP therapy - a supplementary analysis of JCOG0601. Ann Hematol. 2024
Alaggio R, Tsukasaki K, et al. Alaggio R, Tsukasaki K, et al. Correction: "The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms" Leukemia. 2022 Jul;36(7):1720-1748. Leukemia. 2023. 37. 9. 1944-1951
Ogura M, Yamamoto K, Morishima Y, Wakabayashi M, Tobinai K, Ando K, Uike N, Kurosawa M, Gomyo H, Taniwaki M, et al. Long-term follow-up after R-High CHOP/CHASER/LEED with Auto-PBSCT in untreated mantle cell lymphoma-Final analysis of JCOG0406. Cancer Sci. 2023. 114. 8. 3461-3465
Izutsu K, Makita S, Nosaka K, Yoshimitsu M, Utsunomiya A, Kusumoto S, Morishima S, Tsukasaki K, Kawamata T, Ono T, et al. An Open-Label, Single-Arm, Phase 2 Trial of Valemetostat in Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma. Blood. 2023. 141(10):1159-1168
Utsunomiya A, Izutsu K, Jo T, Yoshida S, Tsukasaki K, Ando K, Choi I, Imaizumi Y, Kato K, Kurosawa M, et al. Oral histone deacetylase inhibitor tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia/lymphoma: Phase IIb results. Cancer Science. 2022
Books (9)：
Adult T-cell leukaemia/lymphoma, in Haematolymphoid Tumours (5th ed.), WHO Classification oh Tumours
online. IARC publications 2022
,Adult T-cell leukaemia/lymphoma, in Haematolymphoid Tumours (5th ed.), WHO Classification oh Tumours
online. IARC publications 2022
Valemetostat for Relapsed or Refractory B-Cell Lymphomas: Primary Results from a Phase 1 Trial,
(65th ASH Annual Meeting and Exposition 2023)
Valemetostat for Relapsed or Refractory Peripheral T-Cell Lymphomas: Primary Results from a Phase 1 Trial,
(65th ASH Annual Meeting and Exposition 2023)
Final Analysis of the Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab for DLBCL: JCOG0601
(65th ASH Annual Meeting and Exposition 2023)
,Indolent T-cell lymphoproliferative disorders of the gastrointestinal tract(ITLPD-GIT)2症例における5年を超える長期観察,
(第63回日本リンパ網内系学会学術集会・総会,埼玉,ポスター,2023年6月22日-6月24日 2023)
American Society of Hematology
, 長崎医学会
, 日本造血幹細胞移植学会
, 日本血液学会
, 日本臨床腫瘍学会
, 日本癌学会
, 日本検査血液学会
, 日本内科学会
, 日本リンパ網内系学会
, 日本HTLV-1学会
, American Society of Clinical Oncology
, 日本皮膚悪性腫瘍学会
, American Society oh Hematology
